Abstract:With idiopathic Parkinson's disease being a common entity, parkinsonism in acquired hepatocerebral degeneration (AHD) in the context of Manganese (Mn) has gained importance in recent years. An insight into the pathomechanisms behind this disease has been put forth. How can Mn as a divalent metal exert its effect in leading to chronic neurodegenerative disorder? Secondary to decreased excretion in liver cirrhosis, Mn significantly alters the striatal dopaminergic system. Management of this debilitating disease also focuses on different aspects where Mn has been involved in the pathogenesis. We have put forth the details behind Mn effects in Parkinson's, which will be a guide for better understanding and management of this disease. A literature search was performed using PubMed as a sole database, and all the articles were peer-reviewed. The author tried to follow the PRISMA guidelines. Inclusion criteria were set for 10 years, with most studies with in the last seven years. All types of study designs were included relevant to the topic, clearly delineating the pathomechanisms of Mn in the disease and also its management. After extensive research, through the PubMed database, we found that Parkinson's disease is one of the neurological complications in advanced liver cirrhosis. Mn is an essential element behind its pathogenesis; it works at different cellular levels to promote neurotoxicity. From its influx to its effects on dopamine transporters (DAT), where it disrupts dopamine homeostasis also altering postsynaptic dopamine (D2) receptors, it disrupts mitochondria and the endoplasmic reticulum (ER) promotes oxidative stress and neuroinflammation. Misfolding of alpha-synuclein (α-Syn) is promoted on chronic exposure to Mn where α-Syn from being neuroprotective becomes neurotoxic. It also alters glutaminergic and gabaergic neurotransmission. In a nutshell, the diversity of its effect on nigrostriatal denervation is challenging. The importance of neuroimaging and various approaches to management is also discussed. AHD, an uncommon entity in advanced liver cirrhosis, needs more awareness so that it can be diagnosed earlier and better therapeutic options can be sought. Our study highlighted Mn mechanisms behind this clinical entity, putting forth grounds for a better understanding of this disease. Advanced research targeting Mn for managing this disease will be revolutionary.

Manganese-Induced Parkinsonism and Parkinson’s Disease: Shared and Distinguishable Features

Manganese and Parkinson’s Disease: A Critical Review and New Findings

The Neuropathology of Manganese-Induced Parkinsonism

Manganese-Induced Parkinsonism: Evidence from Epidemiological and Experimental Studies

Role of manganese in neurodegenerative diseases

Manganese and Parkinson's disease: a critical review and new findings

From Manganism to Manganese-Induced Parkinsonism: A Conceptual Model Based on the Evolution of Exposure

Microglial Activation Induced by Neurodegeneration

Manganese, a Likely Cause of 'Parkinson's in Cirrhosis', a Unique Clinical Entity of Acquired Hepatocerebral Degeneration

Manganese and related neurotoxic pathways: A potential therapeutic target in neurodegenerative diseases

Manganese Exposure Causes Movement Deficit and Changes in the Protein Profile of the External Globus Pallidus in Sprague Dawley Rats.

[The Comparison of Neurobehavioral Changes and Impaired Locations Between the Mouse Model of Manganism and Parkinson's Disease].

Manganese overexposure induces Parkinson-like symptoms, altered lipid signature and oxidative stress in C57BL/6 J mouse

Manganese Causes Neurotoxic Iron Accumulation Via Translational Repression of Amyloid Precursor Protein and H‐Ferritin

Manganese exposure leads to depressive-like behavior through disruption of the Gln-Glu-GABA metabolic cycle

Manganese Induces Dopaminergic Neurodegeneration Via Microglial Activation in a Rat Model of Manganism.

The impact of manganese on vascular endothelium

Relevance to Metal-Induced Parkinsonism

Manganese Intoxication Recovery and the Expression Changes of Park2/Parkin in Rats

The tolerable upper intake level of manganese alleviates Parkinson-like motor performance and neuronal loss by activating mitophagy